1. |
郑荣寿, 孙可欣, 张思维, 等. 2015 年中国恶性肿瘤流行情况分析. 中华肿瘤杂志, 2019, 41(1): 19-28.
|
2. |
Rodriguez-Bigas MA, Maamoun S, Weber TK, <italic>et al</italic>. Clinical significance of colorectal cancer: metastases in lymph nodes < 5 mmin size. Ann Surg Oncol, 1996, 3(2): 124-130.
|
3. |
Brown HG, Luckasevic TM, Medich DS, <italic>et al</italic>. Efficacy of manual dissection of lymph nodes in colon cancer resections. Mod Pathol, 2004, 17(4): 402-406.
|
4. |
Yamamoto H, Murata K, Fukunaga M, <italic>et al</italic>. Micrometastasis volume in lymph nodes determines disease recurrence rate of stage Ⅱ colorectal cancer: a prospective multicenter trial. Clin Cancer Res, 2016, 22(13): 3201-3208.
|
5. |
Saha S, Elgamal M, Cherry M, <italic>et al</italic>. Challenging the conventional treatment of colon cancer by sentinel lymph node mapping and its role of detecting micrometastases for adjuvant chemotherapy. Clin Exp Metastasis, 2018, 35(5-6): 463-469.
|
6. |
丛冠宁, 秦明伟, 贺丹, 等. 高分辨 MRI 对直肠癌 TNM 分期及环周切缘的评估. 中国普外基础与临床杂志, 2010, 17(9): 894-900.
|
7. |
Philips BWJ, Fortuin AS, Orzada S, <italic>et al</italic>. High resolution MR imaging of pelvic lymph nodes at 7 Tesla. Magn Reson Med, 2017, 78(3): 1020-1028.
|
8. |
Jin M, Frankel WL. Lymph node metastasis in colorectal cancer. Surg Oncol Clin N Am, 2018, 27(2): 401-412.
|
9. |
Kim HJ, Choi GS. Clinical implications of lymph node metastasis in colorectal cancer: current status and future perspectives. Ann Coloproctol, 2019, 35(3): 109-117.
|
10. |
Shida D, Kanemitsu Y, Hamaguchi T, <italic>et al</italic>. Introducing the eighth edition of the tumor-node-metastasis classification as relevant to colorectal cancer, anal cancer and appendiceal cancer: a comparison study with the seventh edition of the tumor-node-metastasis and the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma. Jpn J Clin Oncol, 2019, 49(4): 321-328.
|
11. |
Triantafyllou M, Studer UE, Birkhäuser FD, <italic>et al</italic>. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur J Cancer, 2013, 49(3): 616-624.
|
12. |
Merkle EM, Dale BM, Paulson EK. Abdominal MR imaging at 3T. Magn Reson Imaging Clin N Am, 2006, 14(1): 17-26.
|
13. |
Steensma BR, Luttje M, Voogt IJ, <italic>et al</italic>. Comparing signal-to-noise ratio for prostate imaging at 7T and 3T. J Magn Reson Imaging, 2019, 49(5): 1446-1455.
|
14. |
Philips BWJ, Stijns RCH, Rietsch SHG, <italic>et al</italic>. USPIO-enhanced MRI of pelvic lymph nodes at 7-T: preliminary experience. Eur Radiol, 2019, 29(12): 6529-6538.
|
15. |
Blank J, Berger N, Knechtges P, <italic>et al</italic>. Initial experience with staging rectal adenocarcinoma using 7T magnetic resonance imaging. J Surg Res, 2020, 245: 434-440.
|
16. |
Tang Y, Rao S, Yang C, <italic>et al</italic>. Value of MRI morphologic features with pT1-2 rectal cancer in determining lymph node metastasis. J Surg Oncol, 2018, 118(3): 544-550.
|
17. |
Brown G, Richards CJ, Bourne MW, <italic>et al</italic>. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology, 2003, 227(2): 371-377.
|
18. |
Kim JH, Beets GL, Kim MJ, <italic>et al</italic>. High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol, 2004, 52(1): 78-83.
|
19. |
Li XT, Sun YS, Tang L, <italic>et al</italic>. Evaluating local lymph node metastasis with magnetic resonance imaging, endoluminal ultrasound and computed tomography in rectal cancer: a meta-analysis. Colorectal Dis, 2015, 17(6): O129-O135.
|
20. |
Schurink NW, Lambregts DMJ, Beets-Tan RGH. Diffusion-weighted imaging in rectal cancer: current applications and future perspectives. Br J Radiol, 2019, 92(1096): 20180655.
|
21. |
Toth GB, Varallyay CG, Horvath A, <italic>et al</italic>. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int, 2017, 92(1): 47-66.
|
22. |
Bashir MR, Bhatti L, Marin D, <italic>et al</italic>. Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging, 2015, 41(4): 884-898.
|
23. |
Pai AB, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J Blood Med, 2012, 3: 77-85.
|
24. |
Bernd H, De Kerviler E, Gaillard S, <italic>et al</italic>. Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program. Invest Radiol, 2009, 44(6): 336-342.
|
25. |
Czarniecki M, Pesapane F, Wood BJ, <italic>et al</italic>. Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer. Transl Androl Urol, 2018, 7(Suppl 4): S453-S461.
|
26. |
Daldrup-Link HE. Ten things you might not know about iron oxide nanoparticles. Radiology, 2017, 284(3): 616-629.
|
27. |
Alexis F, Rhee JW, Richie JP, <italic>et al</italic>. New frontiers in nanotechnology for cancer treatment. Urol Oncol, 2008, 26(1): 74-85.
|
28. |
Wu LC, Cao YF, Liao C, <italic>et al</italic>. Diagnostic performance of USPIO-enhanced MRI for lymph-node metastases in different body regions: a meta-analysis. Eur J Radiol, 2011, 80(2): 582-589.
|
29. |
Corot C, Robert P, Idée JM, <italic>et al</italic>. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev, 2006, 58(14): 1471-1504.
|
30. |
Kordbacheh H, Baliyan V, Parakh A, <italic>et al</italic>. Pictorial review on abdominal applications of ferumoxytol in MR imaging. Abdom Radiol (NY), 2019, 44(10): 3273-3284.
|
31. |
Kinner S, Maderwald S, Albert J, <italic>et al</italic>. Discrimination of benign and malignant lymph nodes at 7.0T compared to 1.5T magnetic resonance imaging using ultrasmall particles of iron oxide: a feasibility preclinical study. Acad Radiol, 2013, 20(12): 1604-1609.
|
32. |
Dadfar SM, Roemhild K, Drude NI, <italic>et al</italic>. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev, 2019, 138: 302-325.
|
33. |
Pesapane F, Czarniecki M, Suter MB, <italic>et al</italic>. Imaging of distant metastases of prostate cancer. Med Oncol, 2018, 35(11): 148.
|
34. |
Harisinghani MG, Saksena MA, Hahn PF, <italic>et al</italic>. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? AJR Am J Roentgenol, 2006, 186(1): 144-148.
|
35. |
Fortuin AS, Brüggemann R, van der Linden J, <italic>et al</italic>. Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2018, 10(1): e1471.
|
36. |
Thoeny HC, Barbieri S, Froehlich JM, <italic>et al</italic>. Functional and targeted lymph node imaging in prostate cancer: current status and future challenges. Radiology, 2017, 285(3): 728-743.
|
37. |
Caglic I, Barrett T. Diffusion-weighted imaging (DWI) in lymph node staging for prostate cancer. Transl Androl Urol, 2018, 7(5): 814-823.
|